Marker Therapeutics, Inc. (MRKR)

US — Healthcare Sector

Peers: EVGN MBIO CLRB AEON GLTO SNSE BOLT COCP PHIO IMNN

Automate Your Wheel Strategy on MRKR

With Tiblio's Option Bot, you can configure your own wheel strategy including MRKR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol MRKR
Rev/Share 0.3861
Book/Share 0.7516
PB 1.2395
Debt/Equity 0.0
CurrentRatio 3.4525
ROIC -1.4473

MktCap 10060252.0
FreeCF/Share -0.7798
PFCF -0.9243
PE -0.8902
Debt/Assets 0.0
DivYield 0
ROE -1.1459

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 4
P/B Score 3
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Initiation	MRKR	Canaccord Genuity	--	Buy	--	$8	March 5, 2025

News

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

MRKR
Published: November 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data

image for news Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

MRKR
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28, 2025 Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28, 2025

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

MRKR
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. This virtual investor event will be held on February 25, 2025.

image for news Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

About Marker Therapeutics, Inc. (MRKR)

IPO Date 2002-07-16
Website https://www.markertherapeutics.com
Industry Biotechnology
CEO Juan F. Vera
Employees 5

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.